XTL BIOPHARMACEUTICALS overview

XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update PR Newswire RAMAT GAN, Israel, Nov. 01, 2018 RAMAT GAN , Israel , Nov. 01, 2018 /PRNewswire/ -- TL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the quarter ended September 30, 2018 and provided an update on the development program for its lead drug...

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update PR Newswire RAMAT GAN, Israel, July 24, 2018 RAMAT GAN , Israel , July 24, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the quarter ended June 30, 2018 and provided an update on the development program for its lead drug...

XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update PR Newswire RAMAT GAN, Israel, May 29, 2018 RAMAT GAN , Israel , May 29, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the quarter ended March 31, 2018 and provided an update on the development program for its lead drug...

...

XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements PR Newswire RAANANA, Israel, December 6, 2017 RAANANA, Israel , December 6, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has received notification from the NASDAQ Stock Market LLC ("NASDAQ") that the Company has...

XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire RAANANA, Israel, Nov. 27, 2017 RAANANA, Israel , Nov. 27, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the third quarter ended September 30, 2017 . Financial Overview XTL reported approximately $6,085 thousand in cash and cash...

XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements PR Newswire RAANANA, Israel, Oct. 23, 2017 RAANANA, Israel , Oct. 23, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that on October 17, 2017 , it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market...

XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update PR Newswire RAANANA, Israel, Sept. 26, 2017 RAANANA, Israel , Sept. 26, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA)("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the second quarter ended June 30, 2017 and provided an update on the development...